Sinopharm Group 15on Stock Net Asset

X2S1 Stock  EUR 13.10  0.20  1.55%   
SINOPHARM GROUP 15ON fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Stock. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SINOPHARM GROUP 15ON Company Net Asset Analysis

SINOPHARM GROUP's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Based on the recorded statements, SINOPHARM GROUP 15ON has a Net Asset of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Medical Distribution (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).

SINOPHARM Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.
SINOPHARM GROUP is currently under evaluation in net asset category among its peers.

SINOPHARM Fundamentals

About SINOPHARM GROUP Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP 15ON's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP 15ON based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in SINOPHARM Stock

SINOPHARM GROUP financial ratios help investors to determine whether SINOPHARM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SINOPHARM with respect to the benefits of owning SINOPHARM GROUP security.